|
Dec 11
|
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum
|
|
Nov 30
|
Reviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
|
|
Nov 20
|
Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Nov 20
|
RVPH: Raise & RECOVER Results Review
|
|
Nov 16
|
Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Nov 14
|
Reviva Pharmaceuticals Holdings Inc Reports Q3 2023 Financial Results
|
|
Nov 14
|
Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights
|
|
Apr 25
|
Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia
|